Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective Comparison of ARNI to Alternate Oral Vasodilator Therapies to Determine the Hemodynamic Profile and Relative Tolerability of (ARNIs) in Patients With Decompensated Heart Failure and Low Cardiac Output

Next Previous
Trial Profile

Prospective Comparison of ARNI to Alternate Oral Vasodilator Therapies to Determine the Hemodynamic Profile and Relative Tolerability of (ARNIs) in Patients With Decompensated Heart Failure and Low Cardiac Output

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sacubitril/valsartan (Primary) ; Vasodilators
  • Indications Heart failure; Low cardiac output
  • Focus Therapeutic Use
  • Acronyms PARAVLO-HF

Most Recent Events

  • 01 Oct 2020 Planned End Date changed from 31 Mar 2022 to 10 Sep 2020.
  • 01 Oct 2020 Planned primary completion date changed from 31 Dec 2021 to 10 Sep 2020.
  • 01 Oct 2020 Status changed from recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top